Biopharma News : Biopharma and Pharma news from all around the world :
- Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
- New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
- Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
- New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
- Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting
- Evinova China and Harbour BioMed Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
- Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
- City of Hope Appoints Leading Lung Cancer Expert Dr. Christine M. Lovly to Head National Thoracic Oncology Program
- FillPoint Health Forms Collaborative Partnership with Noble, an Aptar Pharma Company, to Enhance Patient Experience and Drive Treatment Adherence
- Schrödinger to Present at Jefferies London Healthcare Conference
- MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
- Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
- Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
- Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
- BioTalent Canada Welcomes the Federal Government’s Three-year Funding Commitment for the Student Work Placement Program
- Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
- KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle
- Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
- Merz Aesthetics® Introduces New BELOTERO® Syringe Offering Greater Precision, Comfort and Ease of Use
- Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
- Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
- Where to Get TMS Therapy in Colorado Springs Starts with Serenity Mental Health Centers
- Serenity Mental Health Centers Expands Access in Colorado Springs with FDA-cleared Accelerated Deep TMS Protocol
- Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
- Immunis Publishes Research Showing Body Fat Loss and Reversal of Liver Steatosis and Fibrosis, While Increasing Lean Muscle Mass, in Aged Models
- Appointment of Yves Decadt as Member of Poxel’s Board of Directors
- IVI RMA Research Study Wins Best Paper Prize Award at ASRM 2025 with Juno Genetics
- 20/20 Onsite Tops 20+ CNS Trials, Driving Quality Ocular Endpoint Protection at Scale
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A.
- STRATEC REPORTS DEFINITIVE RESULTS FOR FIRST NINE MONTHS OF 2025
- Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025
- RHÖN-KLINIKUM AG closes third quarter of 2025 with solid results
- Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
- SKAN will miss sales and profit expectations for 2025 – order intake and backlog are developing very positively and laying a strong foundation for 2026
- DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2026
- Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
- SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO
- SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma
- Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities
- Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
- In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
- Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
- MEDICLIN on track: business development in line with expectations
- Mallia Aesthetics Launches 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum
- Cantourage strengthens market presence in Poland with flower variety “Gelato 33”
- Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
- Thomas Meier becomes new CEO of Medios AG
- Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
- Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro
- AEVIS VICTORIA SA (AEVS.SW) – Continued revenue growth in the third quarter of 2025
- STRATEC REPORTS SUPPLY CHAIN-RELATED PRODUCTION DELAYS, ADJUSTMENT TO 2025 SALES GUIDANCE AND PRELIMINARY RESULTS FOR 9M/2025
- Q3 2025: Cantourage delivers strong operating performance in a challenging regulatory market environment
- Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
- Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
- Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
- Mallia Will Pitch as Falling Walls Finalist, Heads to BIO-Europe Ahead of Upcoming Product Launch
- Immunic to Participate in Industry and Investor Conferences in November
- Evotec SE to announce results for the first nine months 2025 on 05 November 2025
- George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025
- Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD – The Liver Meeting® 2025
- Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
- Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
- Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
- Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
- Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
- Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates
- Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
- MemoMaster Unveiled: How This Memo Master Cutting-Edge Brain Support Supplement Is Redefining Focus and Memory Health for the Digital Era
- Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
- Fangzhou Awarded “Golden Bull Award” for Leadership in AI-Powered Chronic Disease Management
- Smile Spa Camarillo Officially Opens its Doors, Offering State-of-the-Art Dental Care in Ventura County
- Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
- Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
- AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
- Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
- Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
- Spyre Therapeutics Announces Grants of Inducement Awards
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025
- Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
- Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
- Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
- IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
- Treace Announces Participation in Two Upcoming Investor Conferences
- Celldex to Present at Upcoming Investor Conferences
- Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
- Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News